Equities

Novacyt SA

Novacyt SA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)0.576
  • Today's Change-0.003 / -0.52%
  • Shares traded102.56k
  • 1 Year change+2.86%
  • Beta-2.6326
Data delayed at least 15 minutes, as of Nov 22 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Novacyt SA is a France-based company providing biotechnological solutions. The Company develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The Company provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The Company develops secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The Company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of distributors.

  • Revenue in EUR (TTM)22.31m
  • Net income in EUR-44.90m
  • Incorporated2006
  • Employees240.00
  • Location
    Novacyt SA13 avenue Morane SaulnierVELIZY VILLACOUBLAY 78140FranceFRA
  • Phone+33 139465104
  • Fax+33 130700532
  • Websitehttps://novacyt.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Poxel SA1.98m-35.09m12.27m22.00------6.19-1.08-1.080.0591-1.270.1002--5.0990,045.45-177.50-52.39---92.200.0505---1,771.33-299.15---1.39----193.92-49.84-11.76------
Plant Advanced Technologies PAT SA2.53m1.09m13.70m27.0012.34--8.695.410.99670.99672.32--------93,777.41---3.53---4.39110.03134.2143.01-33.16--12.90----8.568.05119.67-38.00----
Predilife SA317.79k-4.22m15.55m19.00------48.92-1.14-1.140.0858-1.060.0695--2.0517,030.55-92.43-89.36-129.39-123.8197.2583.94-1,329.21-1,901.22---6.232.20--10.1179.85-15.58---18.51--
Phaxiam Therapeutics SA2.14m-21.92m17.22m54.00--0.6763--8.04-3.46-3.460.39562.540.0409--8.5641,980.39-41.90-50.69-61.11-66.25-----1,023.96-1,009.09---70.910.4556---80.05-21.50-10,201.75---56.68--
Oncodesign Precision Medicine Opm SA468.73k-7.78m18.46m19.00--5.86--39.39-0.449-0.4490.02690.17330.0311--0.455321,305.91-51.68---85.27--153.18---1,660.23-----360.870.715---86.57---3,399.73------
Nfl Biosciences SAS0.00-2.37m19.18m4.00--5.51-----0.2653-0.26530.000.35840.00----0.00-44.70-83.27-70.88-122.37------------0.0151-------53.28------
Valbiotis SA527.00k-8.94m19.55m52.00--1.16--37.10-0.6571-0.65710.03731.070.02082.520.244710,134.62-35.21-32.92-46.61-46.36-511.9553.15-1,697.15-418.874.54-91.620.266--502.93126.7340.16---21.71--
Fermentalg SA8.04m-14.14m25.42m58.00--0.6626--3.16-0.2787-0.27870.15210.44520.13951.344.82129,629.00-22.80-21.94-25.70-24.7114.0414.73-163.46-248.953.42-53.950.2639---46.9475.18-43.29---10.93--
genOway SA21.42m1.26m34.78m128.0026.141.849.281.620.14350.14352.452.040.66581.393.26161,089.303.900.21665.400.304892.3494.825.860.41771.81--0.2639--17.5513.16101.5522.35-14.31--
Gensight Biologics SA804.00k-20.11m36.81m11.00------45.79-0.3537-0.35370.0123-0.24020.0507--21.7350,250.00-126.79-79.44---144.54-----2,501.00-1,036.27---1,250.38-----50.93--5.09---58.28--
Novacyt SA22.31m-44.90m40.96m240.00--0.4836--1.84-0.6357-0.64050.31591.200.1603-3.661.0282,619.26-32.2710.94-38.4414.49153.7861.98-201.2717.643.82-23.910.1573---44.97-0.9408-25.22--2.09--
Abionyx Pharma SA4.86m-3.36m43.52m61.00--4.25--8.96-0.1063-0.10630.15480.29340.331621.806.0580,264.46-22.93-18.82-33.15-28.8719.1914.32-69.15-128.542.22-114.070.2513---11.6592.8416.36--41.40--
Eurofins-Cerep SA42.42m7.25m99.87m218.0013.771.4810.802.351,438.101,438.108,415.7613,378.570.56181.525.41186,032.709.6114.2111.0817.5185.4873.6117.1019.776.89--0.0047---7.4711.60-33.7214.64----
Data as of Nov 22 2024. Currency figures normalised to Novacyt SA's reporting currency: Euro EUR

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
Gestys SAas of 30 Aug 202412.00k0.02%
Data from 30 Aug 2024 - 30 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.